January 19, 2021
Daiichi Sankyo and AstraZeneca said on January 18 that the US FDA has approved their antibody drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) for an additional indication of certain patients with HER2-positive gastric cancer. With the greenlight, Enhertu became the first...read more